The science

Cancer cells have a supply problem.

Aminex targets a metabolic dependence of cancer cells, one of the established hallmarks of cancer: their reliance on polyamines for growth and immune evasion.

Blue scientific illustration of cancer cells
The mechanism

How tumors get polyamines.

01

Internal synthesis

Cancer cells make polyamines internally through the ODC enzyme.

02

External uptake

When synthesis is blocked, tumors import polyamines from the bloodstream.

03

Immune environment

High polyamine levels create an immunosuppressive tumor microenvironment.

Dual blockade

Closing both routes at once.

DFMO blocks internal production; AMXT 1501 blocks external uptake, including through the ATP13A3 transporter. Depleting both releases the immune brake.

Scientific mechanism illustration showing polyamine uptake and synthesis blockade

Immune effects (about 10-fold fewer MDSCs; CD3/CD8 T-cell influx) shown in preclinical models; CD3/CD8 increase also observed in a Phase I melanoma biopsy. Sources: Piha-Paul et al. (2025) ; earlier preclinical references pending confirmation.

Independent validation

Evidence from multiple directions.

Regulatory precedent

FDA approved DFMO (IWILFIN) in December 2023, the first oncology drug acting on the polyamine pathway.

FDA label →

Peer-reviewed research

In 2025, KU Leuven and Children's Cancer Institute researchers showed ATP13A3 drives DFMO-induced uptake, and that AMXT 1501 inhibits it.

Read publication →

Academic trial

Penn State and the Beat Childhood Cancer Consortium sponsor and fund a pediatric Phase 1/2 trial of the combination.

Trial record →
Scientific record

Publications.